Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how much funding his Department has allocated to support the (a) development and (b) expansion of MND clinical trial infrastructure.

The Department funds health and care research infrastructure through the National Institute for Health and Care Research (NIHR). This provides world-class research expertise, specialist facilities, a dedicated research delivery workforce, and support services across the National Health Service and wider health and care system in England.

NIHR infrastructure funding is not allocated by individual disease or therapy area. Instead, it underpins the development and expansion of research capacity across all specialties, including motor neurone disease (MND). Examples include:

- Biomedical Research Centres (BRCs), with £909 million awarded from December 2022 to March 2028. Six BRCs conduct research into neurological disease, supporting discovery science and the development of new trial approaches;

- the Research Delivery Network, with approximately £380 million provided each year, providing the NHS with support funding and the workforce to expand research delivery capability across regions, including for MND studies; and

- Clinical Research Facilities, with £214 million invested until 2029 in 28 facilities, creating dedicated spaces for early-phase and complex trials such as drug, cell, and gene therapies, supporting both the development and expansion of MND clinical trials.

Government responsibility for MND research is shared between the Department of Health and Social Care, with research delivered by NIHR, and the Department for Science, Innovation and Technology, with research delivered by UK Research and Innovation (UKRI). In addition, targeted investments are helping to strengthen trial capacity, including £6 million for the MND Translational Accelerator, which connects UK institutes to speed up the development of treatments, and £8 million for the EXPERTS-ALS programme, which screens promising drugs and complements the MND-SMART platform trial.